TriSalus Life Sciences (TLSIW) Free Cash Flow (2021 - 2026)

TriSalus Life Sciences has reported Free Cash Flow for 6 years, with the latest figure at -$6.6 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 26.04% year-over-year to -$6.6 million; the trailing twelve-month figure through Mar 2026 stood at -$19.4 million (up 45.33% YoY), and the FY2025 full-year result was -$18.1 million, up 56.1% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$6.6 million, down from -$2.5 million in the prior quarter.
• The five-year high for Free Cash Flow was -$425954.0 in Q1 2022, with the low at -$22.9 million in Q3 2022.
• Historically, Free Cash Flow has averaged -$8.8 million across 5 years, with a median of -$8.5 million in 2022.
• Annual changes were most pronounced in 2022 — Free Cash Flow plunged 6166.19% — and 2025, when it surged 65.41%.
• TriSalus Life Sciences' Free Cash Flow stood at -$8.5 million in 2022, then fell by 12.16% to -$9.5 million in 2023, then soared by 36.62% to -$6.1 million in 2024, then jumped by 58.87% to -$2.5 million in 2025, then tumbled by 166.01% to -$6.6 million in 2026.
• The last three Free Cash Flow figures came in at -$6.6 million (Q1 2026), -$2.5 million (Q4 2025), and -$3.8 million (Q3 2025), per Business Quant data.